We are here to help! If you can answer ‘yes’ to any of the following, we can provide educational information to your Urologist.
Are you:
Newly diagnosed with prostate cancer?
Currently on active surveillance?
If you are interested and would like us to reach out to your provider, please fill out their information below
You agree to be contacted with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in any email we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Policy.
You’ll receive a personalized follow up call from a Myriad customer service representative, with the caller ID displaying Myriad Genetics Support Team – Prolaris Test.
Contact Information
Prolaris is an advanced genetic test that combines tools like Gleason score testing and PSA with a personalized tumor score to determine how aggressive your prostate cancer is and the best way to treat it. Prolaris is the only test on the market that can quantify your benefit of adding Androgen Deprivation Therapy (ADT) to radiation therapy (RT), or if you can safely avoid it.
The insights from your Prolaris test result can help you and your provider make a more informed decision about whether ADT is needed for your specific cancer. If your Prolaris test result indicates your cancer is less aggressive, you may be able to safely avoid ADT and its side effects. On the other hand, if the results show your cancer is found to be more aggressive, you and your doctor may choose to proceed with ADT knowing the benefits to your treatment plan warrant its possible impacts.
Request a Prolaris patient guide today to assess your unique risk factors.
ADT is a form of hormone therapy used in prostate cancer treatment that typically accompanies radiation therapy (RT). ADT works by reducing hormone levels, like testosterone, to slow the progression of the cancer.
While ADT can be effective at slowing the progression of prostate cancer, it is often associated with a host of side effects that can significantly diminish one’s quality of life. Determining how much someone may benefit from ADT versus the side effects is critical to making the best treatment decision.
65%
In two clinical utility studies, Prolaris results lead to change in management in up to 65% of patients.1,2,3
$0
97% of patients pay $0 out of pocket
Prolaris is the ONLY test to quantify a patient's benefit of adding ADT to radiation therapy4
“Prolaris is the only biomarker that provides a highly personal risk estimate of absolute risk reduction so the individual can really decide whether using or omitting ADT is right for them”
Dr. Jonathan Tward, MD, PhD, FASTROHuntsman Cancer institute at the University of Utah
Talk to your doctor about Prolaris testing and start personalizing your prostate cancer treatment today.
Contact our trusted advisors for personalized support.